Dong Yu
67Patents
17h-index
25Co-inventors
84Inventor score
Filing activity: May 22, 1995 → Oct 18, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7276489B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | Human Necessities | 176 | Expired |
| US5614622A | 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses | Emerging Cross-Sectional Technologies | 64 | Expired |
| US5962674A | Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages | Emerging Cross-Sectional Technologies | 60 | Expired |
| US6140482A | Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same | Chemistry; Metallurgy | 58 | Expired |
| US7812000B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | Human Necessities | 57 | Active |
| US8202850B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | Human Necessities | 55 | Active |
| US5955599A | Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages | Chemistry; Metallurgy | 52 | Expired |
| US8431544B1 | Compositions for inhibiting gene expression and uses thereof | Chemistry; Metallurgy | 45 | Active |
| US7407944B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | Human Necessities | 37 | Expired |
| US7517862B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | Human Necessities | 37 | Expired |
| US7470674B2 | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides | Human Necessities | 32 | Active |
| US7262286B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | Chemistry; Metallurgy | 29 | Expired |
| US7427405B2 | Immunostimulatory oligonucleotide multimers | Human Necessities | 28 | Expired |
| US8008267B2 | Stabilized immunomodulatory oligonucleotides | Chemistry; Metallurgy | 23 | Active |
| US7405285B2 | Immunostimulatory oligonucleotide multimers | Chemistry; Metallurgy | 23 | Active |
| US7354907B2 | Short immunomodulatory oligonucleotides | Human Necessities | 22 | Expired |
| US9453228B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | Chemistry; Metallurgy | 20 | Active |
| US6531589B1 | Base protecting groups and synthons for oligonucleotide synthesis | Emerging Cross-Sectional Technologies | 16 | Expired |
| US7566702B2 | Immunostimulatory oligonucleotide multimers | Human Necessities | 16 | Expired |
| US7498425B2 | Immunostimulatory oligonucleotide multimers | Human Necessities | 16 | Active |
| US7498426B2 | Immunostimulatory oligonucleotide multimers | Human Necessities | 16 | Active |
| US7569554B2 | Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents | Chemistry; Metallurgy | 15 | Expired |
| US8426375B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | Emerging Cross-Sectional Technologies | 14 | Active |
| US7960362B2 | Synthetic agonists of TLR9 | Human Necessities | 14 | Active |
| US8377898B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | Chemistry; Metallurgy | 10 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.